Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106.
J Thorac Oncol. 2014.
PMID: 24736087
Free article.
No abstract available.
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN.
Mitiushkina NV, et al. Among authors: lozhkina am.
Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30.
Biochimie. 2018.
PMID: 30071258
Item in Clipboard
Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Orlov SV, Iyevleva AG, Filippova EA, Lozhkina AM, Odintsova SV, Sokolova TN, Mitiushkina NV, Tiurin VI, Preobrazhenskaya EV, Romanko AA, Martianov AS, Ivantsov AO, Aleksakhina SN, Togo AV, Imyanitov EN.
Orlov SV, et al. Among authors: lozhkina am.
Transl Oncol. 2021 Aug;14(8):101121. doi: 10.1016/j.tranon.2021.101121. Epub 2021 May 21.
Transl Oncol. 2021.
PMID: 34030112
Free PMC article.
Item in Clipboard
Cite
Cite